Kidiamix G Start (Valine, Acetylcysteine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine)

Kidiamix G Start, an amino acid solution for parenteral nutrition, supports protein synthesis and metabolic needs in pediatric patients.

• Parenteral nutrition in infants and children: Supplies essential amino acids to meet nutritional requirements when enteral feeding is not possible.
• Support of growth and development in pediatric patients: Provides building blocks for tissue synthesis and growth during critical developmental periods.
• Post‑operative nutritional support in children: Helps maintain nitrogen balance and promotes recovery after surgery.
• Metabolic disorders requiring amino acid supplementation: Assists in correcting deficiencies in essential amino acids.

• Kidiamix G Start delivers a balanced mixture of essential amino acids directly into the bloodstream, bypassing the gastrointestinal tract. These amino acids serve as substrates for ribosomal protein synthesis, support nitrogen balance, and act as precursors for neurotransmitters and other metabolic intermediates, thereby sustaining growth, tissue repair, and normal metabolic function in pediatric patients receiving parenteral nutrition.

Kidiamix G Start may be associated with a range of adverse reactions, most of which are related to its intravenous administration and the metabolic load of amino acids.

Common Side Effects

• Injection site erythema or pain.
• Transient hyperglycemia due to dextrose in the carrier solution.
• Mild electrolyte disturbances (e.g., potassium shifts).
• Nausea or vomiting when administered rapidly.
• Mild increase in serum urea nitrogen.

Serious or Rare Side Effects

• Anaphylactic or severe hypersensitivity reactions.
• Hyperammonemia in patients with impaired hepatic function.
• Severe electrolyte imbalances (e.g., hyperkalemia, hyperphosphatemia).
• Metabolic acidosis from excessive amino acid catabolism.
• Thrombophlebitis at the infusion site.
• Renal dysfunction in patients with pre‑existing kidney disease.

Kidiamix G Start should be used with careful clinical monitoring to minimise risks.

• Renal function: Assess baseline kidney function and monitor serum creatinine during therapy.
• Hepatic function: Evaluate liver enzymes, especially in patients with known liver disease.
• Electrolyte balance: Check serum electrolytes before and during infusion.
• Inborn errors of metabolism: Avoid in patients with specific amino‑acid metabolic disorders unless specifically indicated.
• Compatibility: Verify compatibility with other intravenous solutions before mixing.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Kidiamix G Start may interact with other intravenous therapies and metabolic modulators.

Major Interactions (Avoid)

• Calcium‑containing solutions: Can precipitate amino acids, leading to catheter blockage.
• High‑dose parenteral glutamine: May increase nitrogen load and risk of hyperammonemia.
• Certain antibiotics (e.g., ceftriaxone) that form insoluble complexes with amino acids.

Moderate Interactions (Monitor Closely)

• Renal replacement therapy: May alter amino acid clearance, requiring dose adjustment.
• Concurrent electrolyte infusions: May necessitate electrolyte monitoring and adjustment.
• Other components of total parenteral nutrition (lipids, dextrose): Require balancing to avoid metabolic overload.